Alnylam Pharmaceuticals (ALNY) Reports Promising Phase 1b Data for Huntington's Disease RNAi Therapy

gurufocus.com · 2026-10-23

On October 23, 2026, Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) announced encouraging preliminary results from its Phase 1b clinical trial of ALN-HTT02 (brezosi

Read the full story at gurufocus.com →